Molecular genetics of uveal melanoma

Current Eye Research

Volumn 27, Issue 2, 2003, Pages 69-74

  Loercher, Amy E ^a   Harbour, J William ^a,b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOSOME ABERRATION; EYE CANCER; GENE MUTATION; HUMAN; MOLECULAR GENETICS; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; UVEA; UVEA MELANOMA;

HUMANS; LOSS OF HETEROZYGOSITY; MELANOMA; MOLECULAR BIOLOGY; NEOPLASM PROTEINS; NUCLEIC ACID HYBRIDIZATION; SPECTRAL KARYOTYPING; UVEAL NEOPLASMS;

EID: 0042379673     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1076/ceyr.27.2.69.15952     Document Type: Short Survey

References (50)

1. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988;32:239-251.
2. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol. 1992;110:245-250.
3. Horsthemke B, Prescher G, Bornfeld N, Becher R. Loss of chromosome 3 alleles and multiplication of chromosome 8 alleles in uveal melanoma. Genes Chromosomes Cancer. 1992;4:217-221.
4. Sisley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM, Potter AM, Rees RC. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer. 1997;19:22-28.
5. Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:313-317.
6. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996;347:1222-1225.
7. Prescher G, Bornfeld N, Friedrichs W, Seeber S, Becher R. Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosome formation. Cancer Genet Cytogenet. 1995;80:40-46.
8. Singh AD, Boghosian-Sell L, Wary KK, Shields CL, De Potter P, Donoso LA, Shields JA, Cannizzaro LA. Cytogenetic findings in primary uveal melanoma. Cancer Genet Cytogenet. 1994;72:109-115.
9. Bayani JM, Squire JA. Applications of SKY in cancer cytogenetics. Cancer Invest. 2002;20:373-386.
10. Naus NC, van Drunen E, de Klein A, Luyten GP, Paridaens DA, Alers JC, Ksander BR, Beverloo HB, Slater RM. Characterization of complex chromosomal abnormalities in uveal melanoma by fluorescence in situ hybridization, spectral karyotyping, and comparative genomic hybridization. Genes Chromosomes Cancer. 2001;30:267-273.
11. Oga A, Kawauchi S, Izumi H, Ping LX, Furuya T, Sasaki K. New perspectives for tumor pathology provided by comparative genomic hybridization. Int J Clin Oncol. 2002;7:133-137.
12. Speicher MR, Prescher G, du Manoir S, Jauch A, Horsthemke B, Bornfeld N, Becher R, Cremer T. Chromosomal gains and losses in uveal melanomas detected by comparative genomic hybridization. Cancer Res. 1994;54:3817-3823.
13. Gordon KB, Thompson CT, Char DH, O'Brien JM, Kroll S, Ghazvini S, Gray JW. Comparative genomic hybridization in the detection of DNA copy number abnormalities in uveal melanoma. Cancer Res. 1994;54:4764-4768.
14. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC, White RL. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature. 1983;305:779-784.
15. Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK. Monosomy 3 in uveal melanoma: Correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci. 2003;44:1008-1011.
16. Parrella P, Sidransky D, Merbs SL. Allelotype of posterior uveal melanoma: Implications for a bifurcated tumor progression pathway. Cancer Res. 1999;59:3032-3037.
17. White VA, McNeil BK, Horsman DE. Acquired homozygosity (isodisomy) of chromosome 3 in uveal melanoma. Cancer Genet Cytogenet. 1998;102:40-45.
18. Tschentscher F, Prescher G, Horsman DE, White VA, Rieder H, Anastassiou G, Schilling H, Bornfeld N, Bartz-Schmidt KU, Horsthemke B, Lohmann DR, Zeschnigk M. Partial deletions of the long and short arm of chromosome 3 point to two tumor suppressor genes in uveal melanoma. Cancer Res. 2001;61:3439-3442.
19. Sisley K, Curtis D, Rennie IG, Rees RC. Loss of heterozygosity of the thyroid hormone receptor B in posterior uveal melanoma. Melanoma Res. 1993;3:457-461.
20. Myatt N, Aristodemou P, Neale MH, Foss AJE, Hungerford JL, Bhattacharya S, Cree IA. Abnormalities of the transforming growth factor-beta pathway inocular melanoma. J Pathol. 2000;192:511-518.
21. Prives C, Hall PA. The p53 pathway. J Pathol. 1999;187:112-126.
22. Janssen K, Kuntze J, Busse H, Schmid KW. p53 oncoprotein overexpression in choroidal melanoma. Mod Pathol. 1996;9:267-272.
23. Brantley MA, Jr., Worley L, Harbour JW. Altered expression of Rb and p53 in uveal melanomas following plaque radiotherapy. Am J Ophthalmol. 2002;133:242-248.
24. Tobal K, Warren W, Cooper CS, McCartney A, Hungerford J, Lightman S. Increased expression and mutation of p53 in choroidal melanoma. Br J Cancer. 1992;66:900-904.
25. Brantley MA, Jr., Harbour JW. Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol. 2000;157:1795-1801.
26. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296-299.
27. Landers JE, Cassel SL, George DL. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res. 1997;57:3562-3568.
28. Coupland SE, Anastassiou G, Stang A, Schilling H, Anagnostopoulos I, Bornfeld N, Stein H. The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. J Pathol. 2000;191:120-126.
29. Harbour JW, Worley L, Ma D, Cohen M. Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch Ophthalmol. 2002;120:1341-1346.
30. Harbour JW, Dean DC. The Rb/E2F pathway: Emerging paradigms and expanding roles. Genes Dev. 2000;14:2545-2562.
31. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
32. Scholes AG, Liloglou T, Maloney P, Hagan S, Nunn J, Hiscott P, Damato BE, Grierson I, Field JK. Loss of heterozygosity on chromosomes 3, 9, 13, and 17, including the retinoblastoma locus, in uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:2472-2477.
33. Brantley MA, Jr., Harbour JW. Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region. Cancer Res. 2000;60:4320-4323.
34. Soufir N, Bressac-de Paillerets B, Desjardins L, Levy C, Bombled J, Gorin I, Schlienger P, Stoppa-Lyonnet D. Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes. Br J Cancer. 2000;82:818-822.
35. Singh AD, Croce CM, Wary KK, Shields JA, Donoso LA, Shields CL, Huebner K, Ohta M. Familial uveal melanoma: Absence of germline mutations involving the cyclin-dependent kinase-4 inhibitor gene (p16). Ophthalmic Genet. 1996;17:39-40.
36. Hearle N, Damato BE, Humphreys J, Wixey J, Green H, Stone J, Easton DF, Houlston RS. Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:458-462.
37. Wang X, Egan KM, Gragoudas ES, Kelsey KT. Constitutional alterations in p16 in patients with uveal melanoma. Melanoma Res. 1996;6:405-410.
38. Merbs SL, Sidransky D. Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma. Invest Ophthalmol Vis Sci. 1999;40:779-783.
39. van der Velden PA, Metzelaar-Blok JA, Bergman W, Monique H, Hurks H, Frants RR, Gruis NA, Jager MJ. Promoter hypermethylation: A common cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res. 2001;61:5303-5306.
40. Henriksson M, Luscher B. Proteins of the Myc network: Essential regulators of cell growth and differentiation. Adv Cancer Res. 1996;68:109-182.
41. Chana JS, Wilson GD, Cree IA, Alexander RA, Myatt N, Neale M, Foss AJ, Hungerford JL. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Br J Ophthalmol. 1999;83:110-114.
42. Royds JA, Sharrard RM, Parsons MA, Lawry J, Rees R, Cottam D, Wagner B, Rennie IG. C-myc oncogene expression inocular melanomas. Graefes Arch Clin Exp Ophthalmol. 1992;230:366-371.
43. Parrella P, Caballero OL, Sidransky D, Merbs SL. Detection of c-myc amplification in uveal melanoma by fluorescent in situ hybridization. Invest Ophthalmol Vis Sci. 2001;42:1679-1684.
44. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13:1899-1911.
45. Jay V, Yi Q, Hunter WS, Zielenska M. Expression of bcl-2 in uveal malignant melanoma. Arch Pathol Lab Med. 1996;120:497-498.
46. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK, Lin YL, Ramaswamy S, Avery W, Ding HF, Jordan SA, Jackson IJ, Korsmeyer SJ, Golub TR, Fisher DE. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell. 2002;109:707-718.
47. Heine B, Coupland SE, Kneiff S, Demel G, Bornfeld N, Hummel M, Stein H. Telomerase expression in uveal melanoma. Br J Ophthalmol. 2000;84:217-223.
48. Scott RJ, Vajdic CM, Armstrong BK, Ainsworth CJ, Meldrum CJ, Aitken JF, Kricker A. BRCA2 mutations in a population-based series of patients with ocular melanoma. Int J Cancer. 2002;102:188-191.
49. Iscovich J, Abdulrazik M, Cour C, Fischbein A, Pe'er J, Goldgar DE. Prevalence of the BRCA2 6174 del T mutation in Israeli uveal melanoma patients. Int J Cancer. 2002;98:42-44.
50. Foster WJ, Fuller CE, Perry A, Harbour JW. Status of the NF1 tumor suppressor locus in uveal melanoma. Arch Ophthalmol. 2003;in press.